Cost-effectiveness analysis of mRNA COVID-19 vaccine versus inactivated COVID-19 vaccine for mass vaccination in Jordan using a decision tree model

Objectives: The purpose of this study was to present data regarding the most cost-effective vaccine for preventing COVID-19-related deaths. Methods: A mass immunization campaign using mRNA and inactivated COVID-19 vaccines was compared to no vaccination in a cost-effectiveness analysis. A...

Full description

Saved in:
Bibliographic Details
Main Authors: Qusai Abdulraheem AbuQamar, Aidalina Mahmud, Saba Madae'en, Norliza Ahmad, Lim Poh Ying, Azimatun Noor Aizuddin
Format: Article
Language:English
Published: Pensoft Publishers 2025-08-01
Series:Pharmacia
Online Access:https://pharmacia.pensoft.net/article/147563/download/pdf/
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849233304395448320
author Qusai Abdulraheem AbuQamar
Aidalina Mahmud
Saba Madae'en
Norliza Ahmad
Lim Poh Ying
Azimatun Noor Aizuddin
author_facet Qusai Abdulraheem AbuQamar
Aidalina Mahmud
Saba Madae'en
Norliza Ahmad
Lim Poh Ying
Azimatun Noor Aizuddin
author_sort Qusai Abdulraheem AbuQamar
collection DOAJ
description Objectives: The purpose of this study was to present data regarding the most cost-effective vaccine for preventing COVID-19-related deaths. Methods: A mass immunization campaign using mRNA and inactivated COVID-19 vaccines was compared to no vaccination in a cost-effectiveness analysis. A hypothetical population of Jordanians aged 18 and over in 2021 was used to create a decision-tree model from the provider’s point of view. The main result was the prevention of COVID-19-related deaths. Government reports, observational primary costing studies employing the micro-costing approach, systematic reviews, and secondary data analysis at the national level were the sources of the model’s inputs. To take uncertainty into consideration, scenario analysis and one-way sensitivity analysis (OWSA) were performed. Results: mRNA vaccination, inactivated vaccination, and no vaccination strategies have corresponding total costs of 339,035,352.00 JOD, 643,192,339.62 JOD, and 1,110,731,145.64 JOD. It is anticipated that these strategies will result in 952, 6,505, and 29,324 deaths, respectively. The inactivated strategy’s incremental cost-effectiveness ratio (ICER) is 20,489.01 JOD per death averted, whereas the mRNA strategy’s is 27,199.20 JOD per death averted, making it the dominant strategy. The ICER was 54,773.45 JOD saved for every extra mortality prevented when comparing mRNA to the inactivated approach. When compared to the other techniques, the mRNA strategy maintained its dominance throughout alterations in the analysis, as demonstrated by the OWSA and the worst-case scenario analysis, suggesting robust outcomes. Conclusion: The mRNA vaccination strategy outperformed the inactivated vaccine and no-vaccination strategies in this study’s context in terms of preventing COVID-19 mortalities.
format Article
id doaj-art-1941d16192ef4e7b9be788ca3f6196f6
institution Kabale University
issn 2603-557X
language English
publishDate 2025-08-01
publisher Pensoft Publishers
record_format Article
series Pharmacia
spelling doaj-art-1941d16192ef4e7b9be788ca3f6196f62025-08-20T07:33:03ZengPensoft PublishersPharmacia2603-557X2025-08-01721710.3897/pharmacia.72.e147563147563Cost-effectiveness analysis of mRNA COVID-19 vaccine versus inactivated COVID-19 vaccine for mass vaccination in Jordan using a decision tree modelQusai Abdulraheem AbuQamar0Aidalina Mahmud1Saba Madae'en2Norliza Ahmad3Lim Poh Ying4Azimatun Noor Aizuddin5Zarqa UniversityUniversity Putra MalaysiaThe Hashemite UniversityUniversity Putra MalaysiaUniversity Putra MalaysiaUniversiti Kebangsaan MalaysiaObjectives: The purpose of this study was to present data regarding the most cost-effective vaccine for preventing COVID-19-related deaths. Methods: A mass immunization campaign using mRNA and inactivated COVID-19 vaccines was compared to no vaccination in a cost-effectiveness analysis. A hypothetical population of Jordanians aged 18 and over in 2021 was used to create a decision-tree model from the provider’s point of view. The main result was the prevention of COVID-19-related deaths. Government reports, observational primary costing studies employing the micro-costing approach, systematic reviews, and secondary data analysis at the national level were the sources of the model’s inputs. To take uncertainty into consideration, scenario analysis and one-way sensitivity analysis (OWSA) were performed. Results: mRNA vaccination, inactivated vaccination, and no vaccination strategies have corresponding total costs of 339,035,352.00 JOD, 643,192,339.62 JOD, and 1,110,731,145.64 JOD. It is anticipated that these strategies will result in 952, 6,505, and 29,324 deaths, respectively. The inactivated strategy’s incremental cost-effectiveness ratio (ICER) is 20,489.01 JOD per death averted, whereas the mRNA strategy’s is 27,199.20 JOD per death averted, making it the dominant strategy. The ICER was 54,773.45 JOD saved for every extra mortality prevented when comparing mRNA to the inactivated approach. When compared to the other techniques, the mRNA strategy maintained its dominance throughout alterations in the analysis, as demonstrated by the OWSA and the worst-case scenario analysis, suggesting robust outcomes. Conclusion: The mRNA vaccination strategy outperformed the inactivated vaccine and no-vaccination strategies in this study’s context in terms of preventing COVID-19 mortalities.https://pharmacia.pensoft.net/article/147563/download/pdf/
spellingShingle Qusai Abdulraheem AbuQamar
Aidalina Mahmud
Saba Madae'en
Norliza Ahmad
Lim Poh Ying
Azimatun Noor Aizuddin
Cost-effectiveness analysis of mRNA COVID-19 vaccine versus inactivated COVID-19 vaccine for mass vaccination in Jordan using a decision tree model
Pharmacia
title Cost-effectiveness analysis of mRNA COVID-19 vaccine versus inactivated COVID-19 vaccine for mass vaccination in Jordan using a decision tree model
title_full Cost-effectiveness analysis of mRNA COVID-19 vaccine versus inactivated COVID-19 vaccine for mass vaccination in Jordan using a decision tree model
title_fullStr Cost-effectiveness analysis of mRNA COVID-19 vaccine versus inactivated COVID-19 vaccine for mass vaccination in Jordan using a decision tree model
title_full_unstemmed Cost-effectiveness analysis of mRNA COVID-19 vaccine versus inactivated COVID-19 vaccine for mass vaccination in Jordan using a decision tree model
title_short Cost-effectiveness analysis of mRNA COVID-19 vaccine versus inactivated COVID-19 vaccine for mass vaccination in Jordan using a decision tree model
title_sort cost effectiveness analysis of mrna covid 19 vaccine versus inactivated covid 19 vaccine for mass vaccination in jordan using a decision tree model
url https://pharmacia.pensoft.net/article/147563/download/pdf/
work_keys_str_mv AT qusaiabdulraheemabuqamar costeffectivenessanalysisofmrnacovid19vaccineversusinactivatedcovid19vaccineformassvaccinationinjordanusingadecisiontreemodel
AT aidalinamahmud costeffectivenessanalysisofmrnacovid19vaccineversusinactivatedcovid19vaccineformassvaccinationinjordanusingadecisiontreemodel
AT sabamadaeen costeffectivenessanalysisofmrnacovid19vaccineversusinactivatedcovid19vaccineformassvaccinationinjordanusingadecisiontreemodel
AT norlizaahmad costeffectivenessanalysisofmrnacovid19vaccineversusinactivatedcovid19vaccineformassvaccinationinjordanusingadecisiontreemodel
AT limpohying costeffectivenessanalysisofmrnacovid19vaccineversusinactivatedcovid19vaccineformassvaccinationinjordanusingadecisiontreemodel
AT azimatunnooraizuddin costeffectivenessanalysisofmrnacovid19vaccineversusinactivatedcovid19vaccineformassvaccinationinjordanusingadecisiontreemodel